Literature DB >> 32748048

Comparison of PET/CT imaging with [18F]FDOPA and cholecystokinin-2 receptor targeting [68Ga]Ga-DOTA-MGS5 in a patient with advanced medullary thyroid carcinoma.

Christian Uprimny1, Elisabeth von Guggenberg2, Anna Svirydenka2, Renata Mikołajczak3, Alicja Hubalewska-Dydejczyk4, Irene Johanna Virgolini2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32748048     DOI： 10.1007/s00259-020-04963-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  5 in total

1.  DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.

Authors:  Maximilian Klingler; Dominik Summer; Christine Rangger; Roland Haubner; Julie Foster; Jane Sosabowski; Clemens Decristoforo; Irene Virgolini; Elisabeth von Guggenberg
Journal:  J Nucl Med       Date:  2018-12-07       Impact factor: 10.057

2.  EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma.

Authors:  Luca Giovanella; Giorgio Treglia; Ioannis Iakovou; Jasna Mihailovic; Frederik A Verburg; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-04       Impact factor: 9.236

3.  Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma.

Authors:  Giorgio Treglia; Paola Castaldi; Maria Felicia Villani; Germano Perotti; Chiara de Waure; Angelina Filice; Valentina Ambrosini; Nadia Cremonini; Monica Santimaria; Annibale Versari; Stefano Fanti; Alessandro Giordano; Vittoria Rufini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-06       Impact factor: 9.236

4.  Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas.

Authors:  J C Reubi; B Waser
Journal:  Int J Cancer       Date:  1996-09-04       Impact factor: 7.396

Review 5.  Targeting CCK receptors in human cancers.

Authors:  Jean Claude Reubi
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295
  5 in total
  6 in total

Review 1.  Imaging medullary thyroid cancer patients with detectable serum markers: state of the art and future perspectives.

Authors:  Michele Klain; Julien Hadoux; Carmela Nappi; Monica Finessi; Raffaele Ambrosio; Martin Schlumberger; Alberto Cuocolo; Désirée Deandreis; Domenico Salvatore
Journal:  Endocrine       Date:  2021-11-08       Impact factor: 3.633

Review 2.  Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals.

Authors:  Elisabeth von Guggenberg; Petra Kolenc; Christof Rottenburger; Renata Mikołajczak; Alicja Hubalewska-Dydejczyk
Journal:  Cancers (Basel)       Date:  2021-11-18       Impact factor: 6.575

Review 3.  Update on the Diagnosis and Management of Medullary Thyroid Cancer: What Has Changed in Recent Years?

Authors:  Krzysztof Kaliszewski; Maksymilian Ludwig; Bartłomiej Ludwig; Agnieszka Mikuła; Maria Greniuk; Jerzy Rudnicki
Journal:  Cancers (Basel)       Date:  2022-07-27       Impact factor: 6.575

Review 4.  Next-Generation Molecular Imaging of Thyroid Cancer.

Authors:  Yuchen Jin; Beibei Liu; Muhsin H Younis; Gang Huang; Jianjun Liu; Weibo Cai; Weijun Wei
Journal:  Cancers (Basel)       Date:  2021-06-25       Impact factor: 6.639

5.  Automated Synthesis of 68Ga-Labeled DOTA-MGS8 and Preclinical Characterization of Cholecystokinin-2 Receptor Targeting.

Authors:  Anton Amadeus Hörmann; Elisabeth Plhak; Maximilian Klingler; Christine Rangger; Joachim Pfister; Gert Schwach; Herbert Kvaternik; Elisabeth von Guggenberg
Journal:  Molecules       Date:  2022-03-21       Impact factor: 4.927

6.  Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK2R Cancer Theranostic Agents: A Preclinical Study.

Authors:  Berthold A Nock; Panagiotis Kanellopoulos; Oleg G Chepurny; Maritina Rouchota; George Loudos; George G Holz; Eric P Krenning; Theodosia Maina
Journal:  Pharmaceutics       Date:  2022-03-18       Impact factor: 6.321
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.